Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

ABSTRACT: The success of tyrosine kinase inhibitors (TKIs) in select patients with non-small-cell lung cancer (NSCLC) has transformed management of the disease, placing new emphasis on understanding the molecular characteristics of tumor specimens. It is now recognized that genetic alterations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) define two unique subtypes of NSCLC that are highly responsive to genotype-directed TKIs. Despite this initial sensitivity, however, the long-term effectiveness of such therapies is universally limited by the development of resistance. Identifying the mechanisms underlying this resistance is an area of intense, ongoing investigation. In this review, we provide an overview of recent experience in the field, focusing on results f

SUBMITTER: Gainor JF 

PROVIDER: S-EPMC3805932 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature